Malaria is an infectious disease caused by parasites of the Plasmodium genus. It is primarily transmitted to humans through the bite of infected female Anopheles mosquitoes. e caused by parasites of the Plasmodium genus. It is primarily transmitted to humans through the bite of infected female Anopheles mosquitoes. There are several species of Plasmodium that can infect humans, with Plasmodium falciparum and Plasmodium vivax being the most common and medically significant.
Headquartered in Hilden, Germany, the company was founded on November 29th, 1984. It specializes in providing sample and assay technologies for a wide range of applications, including molecular diagnostics, genomics, pharmaceutical research, and more.
In the context of malaria diagnosis, QIAGEN offers products and solutions that are used for detecting and diagnosing the presence of the Plasmodium parasites responsible for causing malaria. These products primarily rely on molecular diagnostic techniques, such as polymerase chain reaction (PCR), to detect and identify the genetic material (DNA or RNA) of the malaria parasites in patient samples.
Established in 1999, the company has its headquarters in Santa Clara, California, United States. It provides a wide range of products and services to support scientific research, diagnostics, and laboratory workflows.
Agilent Technologies offers a wide range of laboratory equipment and instruments, including analytical instruments like liquid chromatography-mass spectrometry (LC-MS) and high-performance liquid chromatography (HPLC) systems, which are essential for various research and diagnostic applications related to malaria.
Richard Scott Perkin and Charles Elmer founded the company in 1937. Its headquarters are situated in Waltham, Massachusetts, United States. It is known for offering a wide range of products, services, and technologies that support research, diagnostics, and screening activities in malaria and other fields.
PerkinElmer develops technologies such as microplate readers, liquid handling systems, and molecular biology equipment that can be applied to malaria research and diagnostic workflows.
Headquartered in Basel, Switzerland, the company was set up on February 29th, 1996. It has a significant presence in the pharmaceutical and healthcare sectors worldwide.
Novartis has been actively involved in the research and development of antimalarial drugs. One of its most well-known contributions is the development of Coartem (Artemether/Lumefantrine), an artemisinin-based combination therapy (ACT) used for the treatment of uncomplicated malaria.
This pharma company was established in 1902 with its headquarters in Brentford, London, United Kingdom. It has a strong presence in the global healthcare and pharmaceutical industries.
GlaxoSmithKline’s most significant contributions to malaria treatment is the development of the antimalarial drug Malarone, which is a combination of atovaquone and proguanil. Malarone is used for the prevention and treatment of malaria. It also develops malaria vaccines. Notably, it played a role in the development of the malaria vaccine Mosquirix (also known as RTS, S/AS01). Mosquirix is the first and only approved malaria vaccine to date.
In the field of malaria control and research, several key players, including pharmaceutical companies like Novartis and GlaxoSmithKline (GSK), as well as biotechnology companies like QIAGEN and PerkinElmer, have made substantial contributions. These companies have been involved in developing antimalarial drugs, diagnostic solutions, and vaccines, and they play a crucial role in improving access to effective treatments and advancing the understanding of the disease. Additionally, global health organizations, research institutions, and governments also form an essential part of the malaria landscape. The combined efforts of these players are instrumental in the fight against malaria, aiming to reduce the burden of this infectious disease, particularly in regions where it is endemic.
How we can help?